Paid Clinical Trials St. Louis
Discover 1,419 paid clinical trials in St. Louis. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Sponsor:
Nuvalent Inc.
Location:
Code:
NCT05384626
Conditions
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
NVL-655
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
Rare and Atypical Diabetes Network
Sponsor:
University of South Florida
Location:
Code:
NCT05544266
Conditions
Diabetes Mellitus
Diabetes Mellitus Progression
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Disease
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
Sponsor:
TORL Biotherapeutics, LLC
Location:
Code:
NCT05156866
Conditions
Advanced Solid Tumor
Gastric Cancer
Pancreas Cancer
Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TORL-2-307-ADC
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
Medtronic Terminate AF Study
Sponsor:
Medtronic Cardiac Surgery
Location:
Code:
NCT03546374
Conditions
Persistent Atrial Fibrillation
Longstanding Persistent Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Surgical Ablation
Cardioblate and Cryoflex hand held devices
Harmony TPV Post-Approval Study
Sponsor:
Medtronic Cardiovascular
Location:
Code:
NCT05077774
Conditions
Congenital Heart Disease
Tetrology of Fallot
RVOT Anomaly
Pulmonary Regurgitation
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Harmony TPV System
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression